Ossfinity®
Leader Biomedical’s OssGro® and Ossfinity® line of synthetic bone grafts are produced with MBCP™ Technology, a proprietary method for producing high quality synthetic bone grafts composed of 60% HA and 40% βTCP. Unlike other bulk production methodologies, this process relies on a sophisticated process of synthesis with several heating steps.
Ossfinity® combines OssGro® granules and an absorbable hydrogel to create a putty, which acts as a carrier for rapid vascularisation and mineralisation.
- Comes in a syringe for easy handling
- Easily used to different grafting sites
- Hydrogel ensures both containment and structural integrity
- Superior handling characteristics
- Resorbable
There are no safety concerns or natural constraints to the availability of synthetic bone grafts. Synthetic bone grafts have proven to be an excellent alternative to human bone, especially when used in conjunction with bone marrow or proline-rich proteins (PRPs) to add osteoinductive properties to the graft.
The art of bone regeneration
Leader Biomedical’s OssGro® line is produced with MBCP™ Technology, a method producing biphasic bone substitutes closely resembling natural bone, for optimal bone regeneration. Unlike other bulk production methodologies, this method relies on a controlled process of synthesis, sublimation, and sintering.
Regeneration
- The specific combination of 60% HA and 40% βTCP results in a highly regulated resorption rate
- Release of calcium and phosphate ions promotes controlled bone regeneration
Porosity
- Macroporous structure proven ideal for cell colonisation and improved osteoconductivity
- Microporous structure ensures interstitial fluids flow freely to enable growth factors to reach cells
Permeability
- The fully permeable network of interconnected pores absorbs three times the graft’s weight in fluids, like bone marrow, in under two minutes
Safety
- No risk of residual chemical or organic material
Availability
- No natural limit on availability